{"id":798416,"date":"2025-01-07T08:10:38","date_gmt":"2025-01-07T13:10:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/"},"modified":"2025-01-07T08:10:38","modified_gmt":"2025-01-07T13:10:38","slug":"hummingbird-bioscience-licenses-novel-antibodies-to-immunome","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/","title":{"rendered":"Hummingbird Bioscience Licenses Novel Antibodies to Immunome"},"content":{"rendered":"
\n

SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target.<\/p>\n

Under the terms of the license agreement, Immunome will\u00a0be responsible for the research, development, manufacturing and commercialization of products\u00a0incorporating these antibodies. Hummingbird Bioscience will receive an upfront payment and will be eligible for\u00a0future development and commercial milestone payments, as well as royalties.<\/p>\n

\u201cThis agreement underlines the value of Hummingbird Bioscience\u2019s epitope-focused antibody discovery capabilities. We are pleased to have licensed one of our monoclonal antibodies to Immunome, a team experienced in developing and commercializing novel ADC therapies. The team\u2019s capabilities make them a great partner to further advance these antibodies,\u201d said Piers Ingram, PhD, Chief Executive Officer of Hummingbird Bioscience. \u201cHummingbird Bioscience is committed to advancing our pipeline of preclinical novel drug candidates and clinical-stage therapies to offer patients potentially new transformative biologics for hard-to-treat diseases.\u201d<\/p>\n

Hummingbird Bioscience\u2019s Rational Antibody Discovery (RAD) platform<\/a> uses proprietary AI-enabled algorithms, immunization strategies and Abvantage\u2122 mice to accelerate discovery of epitope-specific, high affinity antibodies. The platform\u2019s integrated workflow is designed to focus antibody responses to optimal functionally relevant epitopes, and multiple RAD-derived therapeutics are currently in clinical development or have been partnered.<\/p>\n

\n About Hummingbird Bioscience <\/strong>
\n
Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. To address key challenges with current antibody-drug conjugate (ADC) therapies, Hummingbird Bioscience is building a pipeline of next-generation ADCs using its proprietary antibody discovery and linker\/payload platforms. The company has a pipeline of ADCs in preclinical development and other novel biologics including monoclonal antibodies, HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Phase I and an out-licensed ADC (HMBD-501) that will enter the clinic in 2025. The Hummingbird Bioscience approach combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, the commitment to rigorous science, teamwork and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.<\/p>\n

For more information, please visit\u00a0www.hummingbirdbioscience.com<\/a>, and follow Hummingbird Bioscience on\u00a0LinkedIn<\/a>,\u00a0X (formerly Twitter)<\/a>, and\u00a0YouTube<\/a>.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
Contacts\r\n\r\nMedia:\r\nCrystal Ho\r\nc.ho@hummingbirdbio.com\r\nmedia@hummingbirdbio.com\r\n+65 6979 5580\r\n\r\nInvestors:\r\ninvestors@hummingbirdbio.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target. Under the terms of the license agreement, Immunome will\u00a0be responsible for the research, development, manufacturing and commercialization of products\u00a0incorporating these antibodies. Hummingbird Bioscience will receive an upfront payment and will be eligible for\u00a0future development and commercial milestone payments, as well as royalties. \u201cThis agreement underlines the value of Hummingbird Bioscience\u2019s epitope-focused antibody discovery capabilities. We are pleased to have licensed … <\/p>\n
Continue reading “Hummingbird Bioscience Licenses Novel Antibodies to Immunome”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798416","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHummingbird Bioscience Licenses Novel Antibodies to Immunome - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hummingbird Bioscience Licenses Novel Antibodies to Immunome - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target. Under the terms of the license agreement, Immunome will\u00a0be responsible for the research, development, manufacturing and commercialization of products\u00a0incorporating these antibodies. Hummingbird Bioscience will receive an upfront payment and will be eligible for\u00a0future development and commercial milestone payments, as well as royalties. \u201cThis agreement underlines the value of Hummingbird Bioscience\u2019s epitope-focused antibody discovery capabilities. We are pleased to have licensed … Continue reading "Hummingbird Bioscience Licenses Novel Antibodies to Immunome"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T13:10:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzY2NSM2NjgxOTQyIzIyMjIyNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hummingbird Bioscience Licenses Novel Antibodies to Immunome\",\"datePublished\":\"2025-01-07T13:10:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/\"},\"wordCount\":438,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzY2NSM2NjgxOTQyIzIyMjIyNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/\",\"name\":\"Hummingbird Bioscience Licenses Novel Antibodies to Immunome - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzY2NSM2NjgxOTQyIzIyMjIyNjQ=\",\"datePublished\":\"2025-01-07T13:10:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzY2NSM2NjgxOTQyIzIyMjIyNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzY2NSM2NjgxOTQyIzIyMjIyNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hummingbird Bioscience Licenses Novel Antibodies to Immunome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hummingbird Bioscience Licenses Novel Antibodies to Immunome - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/","og_locale":"en_US","og_type":"article","og_title":"Hummingbird Bioscience Licenses Novel Antibodies to Immunome - Market Newsdesk","og_description":"SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target. Under the terms of the license agreement, Immunome will\u00a0be responsible for the research, development, manufacturing and commercialization of products\u00a0incorporating these antibodies. Hummingbird Bioscience will receive an upfront payment and will be eligible for\u00a0future development and commercial milestone payments, as well as royalties. \u201cThis agreement underlines the value of Hummingbird Bioscience\u2019s epitope-focused antibody discovery capabilities. We are pleased to have licensed … Continue reading \"Hummingbird Bioscience Licenses Novel Antibodies to Immunome\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-07T13:10:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzY2NSM2NjgxOTQyIzIyMjIyNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hummingbird Bioscience Licenses Novel Antibodies to Immunome","datePublished":"2025-01-07T13:10:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/"},"wordCount":438,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzY2NSM2NjgxOTQyIzIyMjIyNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/","name":"Hummingbird Bioscience Licenses Novel Antibodies to Immunome - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzY2NSM2NjgxOTQyIzIyMjIyNjQ=","datePublished":"2025-01-07T13:10:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzY2NSM2NjgxOTQyIzIyMjIyNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzY2NSM2NjgxOTQyIzIyMjIyNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hummingbird-bioscience-licenses-novel-antibodies-to-immunome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hummingbird Bioscience Licenses Novel Antibodies to Immunome"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798416"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798416\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}